ESTA icon

Establishment Labs

37.44 USD
+0.32
0.86%
At close Jun 13, 4:00 PM EDT
After hours
37.44
+0.00
0.00%
1 day
0.86%
5 days
-2.40%
1 month
7.09%
3 months
7.52%
6 months
-18.61%
Year to date
-17.31%
1 year
-16.28%
5 years
120.75%
10 years
51.27%
 

About: Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.

Employees: 1,034

0
Funds holding %
of 7,296 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

106% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 17

104% more call options, than puts

Call options by funds: $49.4M | Put options by funds: $24.2M

61% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 28

13% more funds holding

Funds holding: 120 [Q4 2024] → 135 (+15) [Q1 2025]

13% more funds holding in top 10

Funds holding in top 10: 8 [Q4 2024] → 9 (+1) [Q1 2025]

0.39% less ownership

Funds ownership: 91.95% [Q4 2024] → 91.56% (-0.39%) [Q1 2025]

11% less capital invested

Capital invested by funds: $1.22B [Q4 2024] → $1.08B (-$139M) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$48
28%
upside
Avg. target
$48
28%
upside
High target
$48
28%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Needham
Mike Matson
28%upside
$48
Buy
Reiterated
13 Jun 2025

Financial journalist opinion

Neutral
Business Wire
3 days ago
Establishment Labs Hosting Investor Day on June 12
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at www.es.
Establishment Labs Hosting Investor Day on June 12
Neutral
Business Wire
1 week ago
Establishment Labs to Present at Jefferies Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the Jefferies Global Healthcare Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Wednesday, June 4, 2025 at 7:35 a.m. ET. A live webcast of the presentati.
Establishment Labs to Present at Jefferies Global Healthcare Conference
Neutral
Seeking Alpha
1 month ago
Establishment Labs Holdings, Inc. (ESTA) Q1 2025 Earnings Call Transcript
Establishment Labs Holdings, Inc. (NASDAQ:ESTA ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Peter Caldini - Chief Executive Officer Rajbir Denhoy - Chief Financial Officer Juan Jose Chacon-Quiros - Former CEO & Founder Conference Call Participants Marie Thibault - BTIG Joshua Jennings - TD Cowen Michael Matson - Needham & Company Allen Gong - JPMorgan Mason Carrico - Stephens Joanne Wuensch - Citibank Matthew Taylor - Jefferies Anthony Petrone - Mizuho Group Operator Good afternoon, and welcome to the Establishment Labs First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Establishment Labs Holdings, Inc. (ESTA) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Lags Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.58 per share a year ago.
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Lags Revenue Estimates
Neutral
Business Wire
1 month ago
Establishment Labs Reports First Quarter 2025 Financial Results
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2025. First Quarter Highlights and Outlook First quarter worldwide revenue of $41.4 million, including $6.2 million of Motiva sales in the United States. 2025 revenue guidance maintained at $205 million to $210.
Establishment Labs Reports First Quarter 2025 Financial Results
Neutral
Business Wire
1 month ago
Establishment Labs Appoints Peter Caldini as Chief Executive Officer
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. “After an extensive search.
Establishment Labs Appoints Peter Caldini as Chief Executive Officer
Negative
Zacks Investment Research
1 month ago
Earnings Preview: Establishment Labs Holdings Inc. (ESTA) Q1 Earnings Expected to Decline
Establishment Labs (ESTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Establishment Labs Holdings Inc. (ESTA) Q1 Earnings Expected to Decline
Neutral
Business Wire
1 month ago
Establishment Labs to Announce First Quarter 2025 Financial Results on May 7
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2025, after the market closes on Wednesday, May 7, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Can.
Establishment Labs to Announce First Quarter 2025 Financial Results on May 7
Neutral
Business Wire
2 months ago
Establishment Labs Provides Preliminary First Quarter Results and Announces an Investor Day on June 12
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, provided preliminary first quarter 2025 sales results and announced that it will host an analyst and investor event in New York City on June 12, 2025. Establishment Labs' preliminary unaudited revenue for the first quarter of 2025 is expected to be approximately $41.4 million, incl.
Establishment Labs Provides Preliminary First Quarter Results and Announces an Investor Day on June 12
Neutral
Business Wire
2 months ago
Establishment Labs Notes Presentation of 5-Year Results from Motiva U.S. IDE Study at The Aesthetic MEET 2025
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of an update on the Motiva US IDE Study. The update will include five-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the re.
Establishment Labs Notes Presentation of 5-Year Results from Motiva U.S. IDE Study at The Aesthetic MEET 2025
Charts implemented using Lightweight Charts™